The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
In contrast to Wave, Sarepta already has several therapies for DMD on the market, which is how it brought in trailing-12-month net income of slightly more than $47 million. It also has a few more ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
The Supreme Court returns Oct. 7 with a docket featuring cases on transgender rights, gun control, pornography rules, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback